A Review of Clinical Trials Involving Genetically Modified Bacteria, Bacteriophages and Their Associated Risk Assessments
Applied Biosafety · 01.12.2024 · 29 (4) · 186-206
DOI: 10.1089/apb.2024.0002 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Applied Biosafety, online erschienen am 08.05.2024. Verfasst von Paul Gulig und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, Florida, USA. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 149 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Discussion of gene-modified investigational products (IPs) in clinical trials has largely focused on nucleic acid-based vectors, viral vectors, and gene-modified cellular products involving mammalian cells. Use of bacteria and bacteriophages as IPs is resurgent, and discussion of the risks associated with genetic modification of these organisms has become pertinent to the biosafety community.
Methods
This review article summarizes the United States Food and Drug Administration classification for IPs comprising bacteria or bacteriophages and provides an overview of clinical trials conducted to date involving genetically modified bacteria. The risk assessment for bacterial or bacteriophage-based IPs is discussed.
Conclusion
The risk assessment process for bacterial or bacteriophage-based IPs is different from that of gene expression vectors and mammalian cells. Greater consideration must be given to the attenuating mutations affecting virulence, replication competency, antibiotic susceptibility, and persistence in the environment. With the recent growth in clinical trials involving genetically modified bacteria, biosafety professionals and Institutional Biosafety Committees with responsibilities including oversight of clinical trials must become familiar with the associated risk assessment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, Florida, USA.
- Advarra, Columbia, Maryland, USA.
- Department of Ophthalmology, Yale University, Yale School of Medicine, New Haven, Connecticut, USA.
ORCID-Profile: Daniel Eisenman
Zitieren
APA
Gulig, P., Swindle, S., Fields, M., & Eisenman, D. (2024). A Review of Clinical Trials Involving Genetically Modified Bacteria, Bacteriophages and Their Associated Risk Assessments. Applied Biosafety, 29(4), 186-206. https://doi.org/10.1089/apb.2024.0002
Vancouver
Gulig P, Swindle S, Fields M, Eisenman D. A Review of Clinical Trials Involving Genetically Modified Bacteria, Bacteriophages and Their Associated Risk Assessments. Applied Biosafety. 2024;29(4):186-206. doi:10.1089/apb.2024.0002
BibTeX
@article{Gulig2024,
author = {Gulig, Paul and Swindle, Scott and Fields, Mark and Eisenman, Daniel},
title = {A Review of Clinical Trials Involving Genetically Modified Bacteria, Bacteriophages and Their Associated Risk Assessments},
journal = {Applied Biosafety},
year = {2024},
volume = {29},
number = {4},
pages = {186--206},
doi = {10.1089/apb.2024.0002}
}
EUVIMED